HIPPUTOPE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HIPPUTOPE (HIPPUTOPE).
HIPPUTOPE is a diagnostic agent used to assess renal function. It is a radiolabeled compound that undergoes glomerular filtration and tubular secretion, allowing measurement of renal plasma flow and tubular function via imaging.
| Metabolism | HIPPUTOPE is not extensively metabolized; it is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. |
| Excretion | Primarily renal excretion (approximately 90% as unchanged drug via glomerular filtration), with minor biliary/fecal elimination (<10%). |
| Half-life | Terminal elimination half-life is 1.5–2.5 hours; prolonged to 6–12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Negligible protein binding (<1%); does not significantly bind to albumin or other plasma proteins. |
| Volume of Distribution | Vd approximately 0.2–0.3 L/kg, indicating distribution primarily in extracellular fluid; minimal tissue binding. |
| Bioavailability | Not applicable; administered exclusively by intravenous injection. Oral bioavailability is 0% due to rapid degradation in GI tract. |
| Onset of Action | Intravenous: immediate (within minutes) after injection. Oral: not applicable (only IV use). |
| Duration of Action | Duration of diagnostic effect is approximately 1–2 hours post-injection; renal visualization persists for several hours in impaired patients. |
100-300 microcuries (3.7-11.1 MBq) intravenous, single dose for renal imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required; excretion is primarily renal but drug is a radiopharmaceutical administered as a single dose. |
| Liver impairment | No dose adjustment required; hepatic metabolism is minimal. |
| Pediatric use | Weight-based: 50 microcuries/kg (1.85 MBq/kg) intravenous, minimum dose 100 microcuries (3.7 MBq). |
| Geriatric use | No specific dose adjustment; use standard adult dose with attention to renal function for imaging interpretation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HIPPUTOPE (HIPPUTOPE).
| Breastfeeding | Iodide compounds are excreted in breast milk. M/P ratio not available. May cause neonatal thyroid suppression. Contraindicated during breastfeeding. |
| Teratogenic Risk | FDA Category C. First trimester: Iodide accumulation in fetal thyroid after week 10-12 may cause fetal goiter and hypothyroidism. Second and third trimesters: Continued risk of neonatal hypothyroidism with prolonged exposure. Avoid use in pregnancy unless clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to HIPPUTOPE or any of its components.
| Precautions | Use with caution in patients with known hypersensitivity to radiopharmaceuticals. Radiation exposure risk should be considered. Adequate hydration is recommended to minimize radiation dose to the bladder. Use in pregnant or lactating women only if the potential benefit justifies the risk. |
Loading safety data…
| Monitor maternal thyroid function (TSH, free T4) and fetal thyroid status (ultrasound for goiter) if prolonged use unavoidable. Neonatal thyroid screening (cord blood TSH/T4) after delivery. |
| Fertility Effects | No published data on fertility effects in humans. High doses may cause transient ovarian suppression in animal studies. |